Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance. Wisconsin Carbone Cancer Center. Mayo Clinic Cancer Center.

Transcription

1 Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance UCSF Helen Diller Family Stanford Cancer Institute Huntsman Cancer Institute at the University of Utah City of Hope UC San Diego Moores Mayo Clinic University of Colorado Mayo Clinic Fred & Pamela Buffett The University of Texas MD Anderson Robert H. Lurie of Northwestern University Siteman at Barnes-Jewish Hospital and Washington University School of Medicine University of Wisconsin Carbone St. Jude Children s Research Hospital/ The University of Tennessee Health Science Center Dana-Farber/Brigham and Women s Massachusetts General Hospital Roswell Park University of Cancer Institute Michigan Yale / Case Smilow Cancer Hospital /University Memorial Sloan Kettering Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Fox Chase Cancer Institute The Ohio State University The Sidney Kimmel - Cancer James Cancer Hospital and Center at Johns Hopkins Solove Research Institute Vanderbilt-Ingram University of Alabama at Birmingham Duke Cancer Institute Mayo Clinic Moffitt xxvii Journal of the National Cancer Network Timothy J. Eberlein, MD, Elected Chairman of the NCCN Board of Directors; New Officers Elected Timothy J. Eberlein, MD, Siteman at Barnes-Jewish Hospital and Washington University School of Medicine, has been elected Chairman of the NCCN Board of Directors. Dr. Eberlein previously served as Vice Chair of the Board and succeeds Samuel M. Silver, MD, PhD, University of Michigan Cancer Center. The change, along with election of new Board officers, was formalized at the NCCN Board of Directors meeting held in conjunction with the NCCN 21st Annual Conference. It has been a pleasure to work with Dr. Silver for the past 3 years and he has left an indelible impact on NCCN from his tenure as Chair of the Board of Directors. We thank him for his service, said Robert W. Carlson, MD, Chief Executive Officer, NCCN. Looking forward, we are eager to continue our program growth under the leadership of Dr. Eberlein. Dr. Eberlein is Director, Alvin J. Siteman ; Spencer T. and Ann W. Olin Distinguished Professor; and Bixby Professor and Chairman, Department of Surgery, Washington University School of Medicine. Elected to the National Academy of Sciences Institute of Medicine in 2004, Dr. Eberlein is an esteemed surgical oncologist specializing in breast cancer. Throughout his tenure with NCCN, Dr. Eberlein has held leadership roles on a number of committees, including the Executive Committee, Governance Committee, and NCCN Guidelines Steering Committee. I am looking forward to working with all of the NCCN board members and NCCN staff, with the goal of improving patient care and the patient experience for all people with cancer, said Dr. Eberlein. Dr. Silver served as Chairman of the Board since 2013 and will remain a member. NCCN Welcomes University of Wisconsin Carbone to Its Alliance of Leading s NCCN, an alliance of the nation s leading cancer centers dedicated to quality, effectiveness, and efficiency of cancer care, announced that University of Wisconsin Carbone (UWCCC) has been elected to institutional membership. NCCN now has 27 Member Institutions serving the needs of people with cancer throughout the United States. We are pleased to welcome University of Wisconsin Carbone as an NCCN Member Institution, said Robert W. Carlson, MD, Chief Executive Officer, NCCN. UWCCC s esteemed cancer center indeed brings unique attributes to the alliance, particularly its comprehensive palliative care program which includes an inpatient unit and consultation service, children s hospital consultative service, and an outpatient onco-palliative care clinic. Our collaboration with University of Wisconsin Carbone will play an integral role as NCCN strengthens its foothold in national oncology policy, said Gary J. Weyhmuller, MBA, SPHR, Executive Cont. on page xxx. JNCCN Journal of the National Cancer Network Volume 14 Number 5

2 xxx Cont. from page xxvii. Vice President/Chief Operating Officer, NCCN. As part of its impressive policy program, UWCCC houses a coalition of more than 100 organizations in Wisconsin working to reduce the burden of cancer by convening governmental affairs experts, cancer care providers, and health care administrators. An integral part of the University of Wisconsin School of Medicine and Public Health, the UWCCC unites more than 280 physicians and scientists who work together in translating discoveries from research laboratories into new treatments that benefit people with cancer. The only National Cancer Institute (NCI)- designated comprehensive cancer center in Wisconsin, the UWCCC provides the best available cancer care to more than 31,000 patients each year and participates in more than 250 clinical trials annually. As one of the original NCI-designated comprehensive cancer centers, we are delighted to have the opportunity to join the esteemed cancer centers of NCCN, which share our devotion to improving the lives of people with cancer through the rapid application of cancer discovery to cancer care and education, said Howard Bailey, MD, Director of the University of Wisconsin Carbone. As an NCCN Member Institution, expert faculty from UWCCC will have the opportunity to represent their institution on the 49 multidisciplinary NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Panels that set the standard of cancer care and oncology policy in the United States. Additionally, UWCCC investigators and patients will have the opportunity to participate in ground-breaking clinical trials offered through the NCCN Oncology Research Program (ORP). Originally announced as an alliance of 13 leading cancer centers in 1995, NCCN is devoted to patient care, research, and education in order to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. For more information about NCCN, NCCN Member Institutions, and NCCN Guidelines, visit NCCN.org. NCCN Holds Fifth Annual State Oncology Society Forum to Discuss Value in Cancer Care, Best Practices On Saturday, April 2, 2016, the 5th annual NCCN State Oncology Society Forum was held in conjunction with the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care. A topic of focus at this year s Forum was how best to create and measure value in oncology care. With rising costs, the current health care climate is calling for indication of quality validation that the most effective treatment is being utilized for people with cancer while, at the same time, mitigating escalating costs. The challenge stakeholders face today is how to reconcile the subjectivity involved while discussing value. Updates from NCCN The Forum began with words of welcome from Samuel M. Silver, MD, PhD, FACP, University of Michigan, Chairman Emeritus and current member of the NCCN Board of Directors. Dr. Silver spoke about the heart of NCCN the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Former President of the Michigan Society of Hematology and Oncology (MSHO), he emphasized the importance of the work of State Oncology Societies and of community practitioners feedback to NCCN in ensuring the NCCN Guidelines remain relevant. Dr. Silver introduced Robert W. Carlson, MD, Chief Executive Officer, NCCN, who spoke about NCCN, its mission, and strategic direction. Dr. Carlson provided an update JNCCN Journal of the National Cancer Network Volume 14 Number 5 Cont. on page xxxii.

3 xxxii Cont. from page xxx. on the NCCN Guidelines, including scope of recommendations across the continuum of care, the process for development, and continuously growing utilization, as well as current and planned derivative products. Dr. Carlson discussed plans to expand NCCN s family of compendia over the next year to include the NCCN Imaging Appropriate Use Criteria Compendium and the NCCN Radiation Therapy Compendium. He also provided an overview of the NCCN Guidelines with NCCN Evidence Blocks, which were released last year for Chronic Myeloid Leukemia and Multiple Myeloma and currently cover 9 tumor types. NCCN Evidence Blocks are visual representations of 5 key measures efficacy, safety, quality and quantity of evidence, consistency of evidence, and affordability and are intended to be a starting point for shared decision-making between physicians and patients considering the patient s own value system. Accountability for Value in Cancer Care Following Dr. Carlson s update, Lee Newcomer, MD, MHA, Senior Vice President, Oncology, Genetics, UnitedHealthcare, and Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Office of the Chief Medical Officer, Aetna, further expounded on value in oncology during their session titled, Payer Perspective: Models for Quality. Dr. Newcomer spoke about the rising price of health care against average household incomes in the United States, noting that the status quo could not continue and that, ultimately, the cost of US health care would exceed annual household incomes. He offered 4 strategies for solution: (1) prior authorization, (2) comparative effectiveness, (3) performance contracting for specialty drugs, and (4) episode payment for oncologists. He pointed out that outcomes measures will be the most effective measures of quality in oncology. Dr. Kolodziej outlined 2 challenges that payers face today expense and delivery stating that the problematic escalation of cancer care delivery costs is, in part, the fault of the system of approval and coverage of required treatment regimens. Dr. Kolodziej stated that current state mandates require coverage of all cancer drugs approved by the FDA; however, he believes the same mandates do not account for quality and are, therefore, requiring coverage for drugs that do not warrant their expense. He also discussed what value should mean that the patient receives the appropriate treatment at the appropriate time, and that patient experience and outcome are optimized. Best Practices in Community Oncology A second round of speakers and discussion was dedicated to State Oncology Societies best practices from the field. Pavan Reddy, MD, former President, Kansas Society of Clinical Oncology, spoke about the Society s efforts to increase community clinical trials and widen the demographic these trials generally see as the norm. Moreover, he discussed common barriers to entry into clinical trials and emphasized the role that physicians play in encouraging and facilitating patient recruitment. Additionally, he introduced the NCI Community Oncology Research Program (CCOP) and discussed how community physicians and hospitals can help patients enroll for clinical trials through it, noting that the state has been taking part in this through Wichita CCOP and the of Kansas. Joseph Uberti, MD, PhD, President, Michigan Society of Hematology and Oncology, introduced the Reimbursement e-bulletin, an educational resource provided by MSCO. This PDF newsletter is sent via and through the MSHO website the first and third Wednesday of every month, and its goal is to help keep its readers informed and to facilitate discussions between physicians, payers, and policy-makers. Patient Advocacy Resources For the first time, this year s State Oncology Society Forum featured available patient resources offered by patient advocacy groups. Jennifer King, PhD, Director, Science and Research, Lung Cancer Alliance, discussed her organization s work to increase Cont. on page xxxix. JNCCN Journal of the National Cancer Network Volume 14 Number 5

4 xxxix lung screening in people at risk for lung cancer, as well their support of the Lung Screening Requirement issued by Centers for Medicare & Medicaid Services (CMS) in Lung Cancer Alliance launched successful campaigns titled, No one deserves to die and Do you smoke? to dispel stigmas surrounding lung cancers and their connection to smoking. The Lung Cancer Alliance provides 360 lung cancer support, including a mobile app designed to assist patients with monitoring their treatments and Clinical Trial Matching Service a prescreening and referral service that identifies clinical trial options. Dr. King was joined at the podium by Marcie R. Reeder, MPH, Executive Director, NCCN Foundation, who discussed NCCN Foundation and its patient resources, specifically the NCCN Guidelines for Patients for Non Small Cell Lung Cancer and Lung Cancer Screening, 2 patient-friendly publications available free-of-charge on NCCN.org/ patients ( which were supported, in part, by Lung Cancer Alliance. Catherine Ormerod, MSS, MLSP, Vice President, Programs and Partnerships, Living Beyond Breast Cancer (LBBC), discussed the organization s efforts and resources available to help those who have been affected by breast cancer, either as a patient, survivor, or caregiver. Explaining the organization s motto, With you, for you, she encouraged the State Oncology Society members to think of it as a message to them, as well. She spoke about LBBC s efforts to provide education on treatment and support, and how they want to be considered a partner in the breast cancer health care sphere. Throughout the discussions there was call for increased patient engagement and education. Following these presentations, C. Lyn Fitzgerald, MJ, Senior Vice President, U.S. & Global Development, NCCN, encouraged attendees to work with patient advocacy organizations as a means of promoting patient education regarding treatment options as well as support program and clinical trial availability. The forum concluded with a self-declared call to action for the State Oncology Societies. Members declared the need to stand up and be a voice in the conversation in dealing with the issues the health care community currently faces. They expressed a desire for increased communication and collaboration between stakeholders. For more NCCN 21st Annual Conference coverage, visit NCCN.org/news. Cont. from page xxxii. NCCN 21st Annual Conference Convened Experts in Key Oncology Issues; New and Updated NCCN Guidelines Presented The NCCN 21st Annual Conference: Advancing the Standard of Cancer Care was hosted by the NCCN from March 31 April 2, 2016, at The Diplomat in Hollywood, Florida. This year s conference was recordbreaking, with the most attendees in its 21-year history, said Robert W. Carlson, MD, Chief Executive Officer, NCCN. The breadth of topics presented at the conference certainly is a reflection of the impact that NCCN and the NCCN Guidelines have had on people with cancer and their families. We look forward to even further growth in 2017 as we move this conference to Orlando. During this year s conference, NCCN convened expert panels on palliative care, cancer care in an election year, and breast cancer screening controversies. Moreover, Cont. on page xliv. JNCCN Journal of the National Cancer Network Volume 14 Number 5

5 xliv Cont. from page xxxix. attendees had the opportunity to attend track sessions on more than 15 cancer types and supportive care topics, as well as the newest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Vulvar Cancer. The NCCN Guidelines for Vulvar Cancer, published in February 2016, were presented by NCCN Guidelines Panel Chairs, Wui-Jin Koh, MD, and Benjamin Greer, MD, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance. These guidelines provide recommendations on the evaluation and treatment of squamous cell carcinoma of the vulva and include principles of surgery, principles of radiation therapy, and systemic therapy. NCCN Guidelines panel experts presented the latest treatment updates for a number of diseases, including breast, cervical, gastrointestinal, genitourinary, lung, and ovarian cancers; hematologic malignancies; as well as supportive care considerations and controversies in breast cancer screening. Among the supportive care sessions was Cancer Pain Management: Strategies for Safe and Effective Opioid Prescribing, presented by Judith Paice, PhD, RN, Robert H. Lurie of Northwestern University. During this presentation, Dr. Paice described best practices for safe assessment in the management of chronic pain in people with cancer in order to avoid drug misuse and abuse. Controversies in Breast Cancer Screening Strategies featured expert representatives from American Cancer Society, NCCN, and US Preventive Services Task Force as they discussed the different breast cancer screening recommendations for US women at average risk for the disease. As part of the ongoing NCCN value initiative, Dr. Carlson presented the NCCN Guidelines with NCCN Evidence Blocks alongside Eric Jonasch, MD, The University of Texas MD Anderson, who further discussed the implementation of the visual representation of 5 key value measurements into the NCCN Guidelines for Kidney Cancer. Moderated by Toby C. Campbell, MD, MSCI, University of Wisconsin Carbone, the opening roundtable held March 31, 2016, titled Palliative Care: Providing Comfort from a Patient and Provider Perspective, featured experts representing both the clinical and patient experience with palliative care. The multidisciplinary panel provided insight into the value of palliative care in the cancer care continuum, noting the importance of a team approach, early intervention, and an open, continuous dialogue. The April 1 sessions commenced with the second expert roundtable, Emerging Issues in Oncology: Cancer Care in an Election Year, which featured pundits from both sides of the aisle as they deliberated on the future of health care in the United States and the challenges that the system will face during this election year. Moderated by Kavita Panel, MD, MSHS, The Brookings Institute, and Marc Samuels, JD, MPH, ADVI, panelists discussed challenges in payment reform, data sharing, and patient access. Also held on site during the 21st Annual Conference were the 2016 Nursing Program: Advancing Oncology Nursing, the 2016 NCCN Oncology Fellows Program: New Horizons in Quality Cancer Care, the fifth annual State Oncology Society Forum, and general poster sessions that featured study outcomes from more than 70 presenters, including the 2014 NCCN Foundation Young Investigator Award recipients. The NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care will be held March 23 25, 2017, at the Rosen Shingle Creek in Orlando, Florida. For additional conference coverage, visit NCCN.org/news. JNCCN Journal of the National Cancer Network Volume 14 Number 5